People: Alkermes Plc (ALKS.O)
31.69USD
17 May 2013
$1.36 (+4.48%)
$30.33
$30.31
$31.78
$29.86
1,388,390
1,307,106
$32.33
$14.82
Pops, Richard
Brief Biography
Mr. Richard F. Pops is Chairman of the Board, Chief Executive Officer of Alkermes Plc., since September 16, 2011. Until September 16, 2011, Mr. Pops was Chief Executive Officer, President and Chairman of the Board of Alkermes. Mr. Pops served as Chief Executive Officer of Alkermes from February 1991 to April 2007 and as Chief Executive Officer and President since September 2009. He was a director of Alkermes from February 1991 to September 2011 and was Chairman of the Board of Alkermes since April 2007. Mr. Pops serves on the board of directors of Neurocrine Biosciences, Inc., a publicly traded biopharmaceutical company, Acceleron Pharma, Inc. and Epizyme Inc., both of which are privately held biotechnology companies, Biotechnology Industry Organization, and PhRMA. He has previously served on the board of directors of two other publicly traded biopharmaceutical companies, Sirtris Pharmaceuticals from 2004 to 2008, and CombinatoRx, Incorporated from 2001 to 2009. Mr. Pops served on the board of directors of Reliant Pharmaceuticals, a privately held pharmaceutical company purchased by GlaxoSmithKline in 2007, and on the advisory board of Polaris Venture Partners. He is a member of the Harvard Medical School Board of Fellows.
Basic Compensation
| Total Annual Compensation, USD | Long-Term Incentive Plans, USD | All Other, USD | Fiscal Year Total, USD |
|---|---|---|---|
| 774,954 | -- | 4,957,490 | 6,320,860 |
Options Compensation
| Quantity | Market Value | |
|---|---|---|
| Excercisable | -- | -- |
| Unexercisable | -- | -- |
| Excercised | 60,000 | 753,142.00 |
| Name | Fiscal Year Total |
|---|---|
Richard Pops |
6,320,860 |
Shane Cooke |
4,465,710 |
James Frates |
1,959,460 |
Gordon Pugh |
1,965,720 |
Kathryn Biberstein |
-- |
James Botkin |
-- |

